SYSTEM AND METHOD FOR DE NOVO DRUG DISCOVERY

Patent №

US 11,615,324

Granted

2023-03-28

Filed 2021

Owner

RO5 INC.

Lab

AI components

4

ml · vision · kr · hardware

Assignment

Recorded

Dataset

AIPD

2023_r1 edition

Application

17174677

A system and method for de novo drug discovery using machine learning algorithms. In a preferred embodiment, de novo drug discovery is performed via data enrichment and interpolation/perturbation of molecule models within the latent space, wherein molecules with certain characteristics can be generated and tested in relation to one or more targeted receptors. Filtering methods may be used to determine active novel molecules by filtering out non-active molecules and contain activity predictors to better navigate the molecule-receptor domain. The system may comprise neural networks trained to reconstruct known ligand-receptors pairs and from the reconstruction model interpolate and perturb the model such that novel and unique molecules are discovered. A second preferred embodiment trains a variational autoencoder coupled with a bioactivity model to predict molecules exhibiting a range of desired properties.

Machine learningVisionKnowledge representationAI hardwareG06N 3/088G06N 5/022G06F 16/951G06F 18/22G06N 3/044G06N 3/0442G06N 3/045G06N 3/0455+15 more

AI classification

Machine learning1.00
AI hardware1.00
Vision0.99
Knowledge representation0.96
Natural language0.11
Evolutionary computation0.00
Speech0.00
Planning0.00

Ownership

RO5 INC.

assignment · 554640862

Assignors

PABRINKIS, AURIMAS, BUCHER, ALWIN, KAMUNTAVICIUS, GINTAUTAS, PRAT, ALVARO, BASTAS, ORESTIS, JOCYS, ZYGIMANTAS, TAL, ROY, KNUFF, CHARLES DAZLER

On an employer assignment, the assignors are typically the inventors.

© 2026 NYSGPT2525 LLC